相关论文: Biochemical Prostate Cancer Recurrence Prediction:…
In this paper, we apply Classification Restricted Boltzmann Machine (ClassRBM) to the problem of predicting breast cancer recurrence. According to the Polish National Cancer Registry, in 2010 only, the breast cancer caused almost 25% of all…
While the 10-year survival rate for localized prostate cancer patients is very good (>98%), side effects of treatment may limit quality of life significantly. Erectile dysfunction (ED) is a common burden associated with increasing age as…
Recently there has been much work on early phase cancer designs that incorporate both toxicity and efficacy data, called Phase I-II designs because they combine elements of both phases. However, they do not explicitly address the Phase II…
Prostate cancer is a leading cause of mortality in men, yet interpretation of T2-weighted prostate MRI remains challenging due to subtle and heterogeneous lesions. We developed an interpretable framework for automatic cancer detection using…
Survival prediction aims to evaluate the risk level of cancer patients. Existing methods primarily rely on pathology and genomics data, either individually or in combination. From the perspective of cancer pathogenesis, epigenetic changes,…
To explain a bimodal pattern of hazard of relapse among early stage breast cancer patients identified in multiple databases, we proposed that late relapses result from steady stochastic progressions from single dormant malignant cells to…
Bladder cancer is one of the most prevalent malignancies worldwide, with a recurrence rate of up to 78%, necessitating accurate post-operative monitoring for effective patient management. Multi-sequence contrast-enhanced MRI is commonly…
Retrosynthetic planning is a critical task in organic chemistry which identifies a series of reactions that can lead to the synthesis of a target product. The vast number of possible chemical transformations makes the size of the search…
Prostate cancer being one of the frequently diagnosed malignancy in men, the rising demand for biopsies places a severe workload on pathologists. The grading procedure is tedious and subjective, motivating the development of automated…
Current deep learning-based models typically analyze medical images in either 2D or 3D albeit disregarding volumetric information or suffering sub-optimal performance due to the anisotropic resolution of MR data. Furthermore, providing an…
Head and neck cancers are the fifth most common cancer worldwide, and recently, analysis of Positron Emission Tomography (PET) and Computed Tomography (CT) images has been proposed to identify patients with a prognosis. Even though the…
Dose-finding clinical trials in oncology aim to estimate the maximum tolerated dose (MTD), based on safety traditionally obtained from the clinician's perspective. While the collection of patient-reported outcomes (PROs) has been advocated…
Cancer, a leading cause of death globally, occurs due to genomic changes and manifests heterogeneously across patients. To advance research on personalized treatment strategies, the effectiveness of various drugs on cells derived from…
Thyroid cancer is currently the fifth most common malignancy diagnosed in women. Since differentiation of cancer sub-types is important for treatment and current, manual methods are time consuming and subjective, automatic computer-aided…
Prostatectomized patients are at risk of resurgence, and for this reason, during a follow-up period, they are monitored for Prostate Specific Antigen (PSA) growth, an indicator of tumor progression. The presence of tumors can be evaluated…
We propose an oAPT workflow that incorporates all these functionalities and validate its clinical implementation feasibility with prostate patients. AI-based auto-segmentation tool AccuContourTM (Manteia, Xiamen, China) was seamlessly…
Cohort-based enrollment can slow down dose-finding trials since the outcomes of the previous cohort must be fully evaluated before the next cohort can be enrolled. This results in frequent suspension of patient enrollment. The issue is…
Background: Phase I dose-finding trials increasingly encounter delayed-onset toxicities, especially with immunotherapies and targeted agents. The time-to-event continual reassessment method (TITE-CRM) handles incomplete follow-up using…
Bladder cancer claims one life every 3 minutes worldwide. Most patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC), yet up to 70% recur after treatment, triggering a relentless cycle of surgeries, monitoring, and risk of…
Objectives: Pancreatic cancer is a lethal disease, hard to diagnose and usually results in poor prognosis and high mortality. Developing an artificial intelligence (AI) algorithm to accurately and universally predict the early cancer risk…